Alphavirus VLPs Modulate Immune Response Without Infection Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Chikungunya virus lack effective solutions for modulation of immune response and treatment or prophylaxis, particularly in large-scale production and clinical application.
Innovation Solution
Development of a method and composition using alphavirus virus-like particles (VLPs) composed of alphavirus structural proteins, such as Chikungunya virus or Venezuelan equine encephalitis virus proteins, to modulate immune responses and treat immune-related diseases, including cancer and infectious diseases, by administering an effective amount of these particles as an immunostimulant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alphavirus VLPs are used to stimulate immune response, then immune response is enhanced, but risk of alphavirus infection increases
Solution Approach 1:
The patent extracts only the structural proteins (capsid, E1, E2) from the complete alphavirus, assembling them into virus-like particles that mimic the viral structure but lack the viral genome. This extraction of the harmful genetic material while retaining the immunogenic structural components resolves the contradiction by enabling immune stimulation without infection risk
Solution Approach 2:
The patent creates accurate copies of the viral structure using recombinant structural proteins that self-assemble into VLPs identical in conformation to authentic viruses. These copies provide the necessary immune recognition without containing functional viral genetic material, thus enhancing immune response while eliminating infection risk
2Productivity
If VLP-based vaccines are produced at large scale, then productivity increases, but manufacturing complexity increases
Solution Approach 1:
The patent uses a universal alphavirus structural protein framework that can be produced through standardized recombinant expression systems. The same basic VLP assembly mechanism applies across different alphavirus types, allowing scalable production through established biomanufacturing processes rather than requiring complex virus-specific protocols
Solution Approach 2:
The structural proteins expressed from recombinant DNA sequences self-assemble into VLPs automatically through their intrinsic ability to form viral-like structures. This self-assembly property eliminates the need for complex assembly procedures, enabling straightforward large-scale production by simply expressing the proteins in suitable host cells
Data Source
AI summary
Provided is a method for modulating an immune response which is not derived from alphavirus infection comprising administering to a subject in need thereof an effective amount of a composition comprising an alphavirus virus like particle.